Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05473585
Other study ID # Pro00105539
Secondary ID 5R01DA048454
Status Completed
Phase N/A
First received
Last updated
Start date October 12, 2022
Est. completion date May 9, 2023

Study information

Verified date July 2023
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate how limiting the nicotine content in regular cigarettes affects choices for regular cigarette and e-cigarette products. Eligible participants will be of legal age to purchase tobacco products and regularly use both e-cigarettes and regular cigarettes.


Description:

Participants in this study will undergo an in-person screening session where the study will be explained in detail and participants will answer questions and provide a breath sample. During the screening session, participants will also be asked to complete surveys. Eligible participants will then complete the training procedures during which they will select an e-cigarette device to use for future preference sessions. During the 4 preference sessions, participants will sample puffs from an e-cigarette and regular cigarette and answer questions about their experience with each. They will also complete a task during which they can choose to earn puffs from the e-cigarette or regular cigarette, or choose to not take any puffs. The 4 sessions will be the same except that a different combination of e-cigarette and regular cigarette is used at each session.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date May 9, 2023
Est. primary completion date May 9, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Legal age to purchase tobacco products; 2. Regular user of EC and CC; 3. Owns the e-cigarette device used most often; 4. Agrees to abstain from using all tobacco products for 12 hours prior to each experimental session; 5. Self-reporting tobacco flavored e-liquid is preferred or usual flavor e-liquid Exclusion Criteria: 1. Unstable medical conditions as determined by the licensed medical professional; 2. Unstable psychiatric conditions as determined by the licensed medical professional or PI; 3. Currently pregnant, breastfeeding, trying to become pregnant or unwilling to agree to use adequate protection to avoid pregnancy; 4. Serious quit attempt of either or both products in the past 3 months resulting in >30 days of abstinence; 5. Currently using nicotine replacement therapy or other pharmacotherapies as cessation aide; 6. Plans to quit use of either EC or CC, or all tobacco products in the next 45 days; 7. Self-reporting nicotine-free, CBD, or THC liquid is preferred or usual e-liquid; 8. Vital signs outside of the following range (participants failing for vital signs will be allowed to re-screen once): 1. Systolic blood pressure (BP) greater than or equal to 160 mm/hg 2. Diastolic BP greater than or equal to 100 mm/hg 3. Heart rate greater than or equal to 115 bpm; 9. Allergy to propylene glycol or vegetable glycerin; 10. Previous adverse reaction when using vaping device or e-liquid; 11. Current or recent alcohol or drug abuse problems; 12. Previous use of SPECTRUM or other reduced nicotine content cigarettes in past 3 months; 13. Literate and able to independently complete and comprehend the consent form and other written study materials and measures.

Study Design


Intervention

Other:
very low nicotine content cigarettes
Investigational combusted cigarettes with very low nicotine content
normal nicotine content cigarettes
Investigational combusted cigarettes with normal nicotine content
Study e-cigarette
E-cigarette provided by study

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Duke University National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of choices for CC during preference task Participants will complete a preference task during which they will choose to take puffs from the session EC, the session CC, or to abstain from taking any puffs. A total of 10 trials will be completed. The number of choices for CC will be compared across the preference sessions. during preference session, approximately 2 hours
Secondary Number of choices for EC during preference task Participants will complete a preference task. The number of choices for EC will be compared across the preference sessions. during preference session, approximately 2 hours
Secondary Number of choices to abstain during preference task Participants will complete a preference task. The number of choices to abstain from any puffs will be compared across the preference sessions. during preference session, approximately 2 hours
Secondary Cigarette Evaluation Scale subjective reactions (e.g., satisfaction, dizziness) to CC product as well as how much a measure of how much they would pay for a day's worth of the product. Scale is administered on a 0-100 scale where 0 is "not at all" and 100 is "extremely" during preference session, approximately 2 hours
Secondary Perceived health risk Participants will rate on a scale from 1 (very low risk) to 7 (very high risk) their perceived risk of developing a variety of health conditions (e.g., lung cancer, heart disease, stroke) as a result of using each product. during preference session, approximately 2 hours
Secondary Craving craving rating on a scale from 1-10 [no urge to extremely strong urge] for CC and EC after product exposure relative to baseline value during preference session, approximately 2 hours
Secondary Product Valuation Participants will be asked how many days per month would they use the CC product they just sampled at a variety of price increments during preference session, approximately 2 hours
Secondary CO boost Breath carbon monoxide (CO) value after product exposure during the preference task relative to baseline value during preference session, approximately 2 hours
Secondary Cross Price Elasticity the change in demand for the session CC in response to a change in price of the session EC during preference session, approximately 2 hours
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02649556 - A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Active, not recruiting NCT02752022 - Monitoring the Transition From Smoking to E-cigarettes
Completed NCT02901171 - The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation N/A
Completed NCT02912000 - TEACH: Technology Evaluation to Address Child Health N/A
Completed NCT04340830 - The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02949648 - Electronic Cigarette Use and Quitting in Youth N/A
Completed NCT02246114 - Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT01898507 - Nicotine Metabolism and Low Nicotine Cigarettes N/A
Completed NCT01954407 - Young Adults' Responses to Anti-smoking Messages N/A
Completed NCT02008292 - Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors N/A